306 related articles for article (PubMed ID: 16835260)
1. Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.
Yang FC; Chen S; Clegg T; Li X; Morgan T; Estwick SA; Yuan J; Khalaf W; Burgin S; Travers J; Parada LF; Ingram DA; Clapp DW
Hum Mol Genet; 2006 Aug; 15(16):2421-37. PubMed ID: 16835260
[TBL] [Abstract][Full Text] [Related]
2. Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1+/- mast cells.
Yang FC; Ingram DA; Chen S; Hingtgen CM; Ratner N; Monk KR; Clegg T; White H; Mead L; Wenning MJ; Williams DA; Kapur R; Atkinson SJ; Clapp DW
J Clin Invest; 2003 Dec; 112(12):1851-61. PubMed ID: 14679180
[TBL] [Abstract][Full Text] [Related]
3. Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow.
Yang FC; Ingram DA; Chen S; Zhu Y; Yuan J; Li X; Yang X; Knowles S; Horn W; Li Y; Zhang S; Yang Y; Vakili ST; Yu M; Burns D; Robertson K; Hutchins G; Parada LF; Clapp DW
Cell; 2008 Oct; 135(3):437-48. PubMed ID: 18984156
[TBL] [Abstract][Full Text] [Related]
4. Mast cells and the neurofibroma microenvironment.
Staser K; Yang FC; Clapp DW
Blood; 2010 Jul; 116(2):157-64. PubMed ID: 20233971
[TBL] [Abstract][Full Text] [Related]
5. Hyperactivation of p21(ras) and the hematopoietic-specific Rho GTPase, Rac2, cooperate to alter the proliferation of neurofibromin-deficient mast cells in vivo and in vitro.
Ingram DA; Hiatt K; King AJ; Fisher L; Shivakumar R; Derstine C; Wenning MJ; Diaz B; Travers JB; Hood A; Marshall M; Williams DA; Clapp DW
J Exp Med; 2001 Jul; 194(1):57-69. PubMed ID: 11435472
[TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo.
Wang S; Wilkes MC; Leof EB; Hirschberg R
FASEB J; 2005 Jan; 19(1):1-11. PubMed ID: 15629889
[TBL] [Abstract][Full Text] [Related]
7. Pak1 regulates multiple c-Kit mediated Ras-MAPK gain-in-function phenotypes in Nf1+/- mast cells.
McDaniel AS; Allen JD; Park SJ; Jaffer ZM; Michels EG; Burgin SJ; Chen S; Bessler WK; Hofmann C; Ingram DA; Chernoff J; Clapp DW
Blood; 2008 Dec; 112(12):4646-54. PubMed ID: 18768391
[TBL] [Abstract][Full Text] [Related]
8. A non-Smad mechanism of fibroblast activation by transforming growth factor-beta via c-Abl and Egr-1: selective modulation by imatinib mesylate.
Bhattacharyya S; Ishida W; Wu M; Wilkes M; Mori Y; Hinchcliff M; Leof E; Varga J
Oncogene; 2009 Mar; 28(10):1285-97. PubMed ID: 19151753
[TBL] [Abstract][Full Text] [Related]
9. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis.
Daniels CE; Wilkes MC; Edens M; Kottom TJ; Murphy SJ; Limper AH; Leof EB
J Clin Invest; 2004 Nov; 114(9):1308-16. PubMed ID: 15520863
[TBL] [Abstract][Full Text] [Related]
10. Nf1-/- Schwann cell-conditioned medium modulates mast cell degranulation by c-Kit-mediated hyperactivation of phosphatidylinositol 3-kinase.
Chen S; Burgin S; McDaniel A; Li X; Yuan J; Chen M; Khalaf W; Clapp DW; Yang FC
Am J Pathol; 2010 Dec; 177(6):3125-32. PubMed ID: 21037083
[TBL] [Abstract][Full Text] [Related]
11. The Nf1 tumor suppressor regulates mouse skin wound healing, fibroblast proliferation, and collagen deposited by fibroblasts.
Atit RP; Crowe MJ; Greenhalgh DG; Wenstrup RJ; Ratner N
J Invest Dermatol; 1999 Jun; 112(6):835-42. PubMed ID: 10383727
[TBL] [Abstract][Full Text] [Related]
12. Neurofibromas in NF1: Schwann cell origin and role of tumor environment.
Zhu Y; Ghosh P; Charnay P; Burns DK; Parada LF
Science; 2002 May; 296(5569):920-2. PubMed ID: 11988578
[TBL] [Abstract][Full Text] [Related]
13. The activation of the WNT signaling pathway is a Hallmark in neurofibromatosis type 1 tumorigenesis.
Luscan A; Shackleford G; Masliah-Planchon J; Laurendeau I; Ortonne N; Varin J; Lallemand F; Leroy K; Dumaine V; Hivelin M; Borderie D; De Raedt T; Valeyrie-Allanore L; Larousserie F; Terris B; Lantieri L; Vidaud M; Vidaud D; Wolkenstein P; Parfait B; Bièche I; Massaad C; Pasmant E
Clin Cancer Res; 2014 Jan; 20(2):358-71. PubMed ID: 24218515
[TBL] [Abstract][Full Text] [Related]
14. Neurofibromin-deficient Schwann cells have increased lysophosphatidic acid dependent survival and migration-implications for increased neurofibroma formation during pregnancy.
Nebesio TD; Ming W; Chen S; Clegg T; Yuan J; Yang Y; Estwick SA; Li Y; Li X; Hingtgen CM; Yang FC
Glia; 2007 Apr; 55(5):527-36. PubMed ID: 17236191
[TBL] [Abstract][Full Text] [Related]
15. Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression.
Staser K; Yang FC; Clapp DW
Annu Rev Pathol; 2012; 7():469-95. PubMed ID: 22077553
[TBL] [Abstract][Full Text] [Related]
16. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
Gottfried ON; Viskochil DH; Couldwell WT
Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
[TBL] [Abstract][Full Text] [Related]
17. Loss of the nf1 tumor suppressor gene decreases fas antigen expression in myeloid cells.
Hiatt K; Ingram DA; Huddleston H; Spandau DF; Kapur R; Clapp DW
Am J Pathol; 2004 Apr; 164(4):1471-9. PubMed ID: 15039234
[TBL] [Abstract][Full Text] [Related]
18. Tranilast, an anti-allergic drug, down-regulates the growth of cultured neurofibroma cells derived from neurofibromatosis type 1.
Yamamoto M; Yamauchi T; Okano K; Takahashi M; Watabe S; Yamamoto Y
Tohoku J Exp Med; 2009 Mar; 217(3):193-201. PubMed ID: 19282654
[TBL] [Abstract][Full Text] [Related]
19. Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis.
Ling BC; Wu J; Miller SJ; Monk KR; Shamekh R; Rizvi TA; Decourten-Myers G; Vogel KS; DeClue JE; Ratner N
Cancer Cell; 2005 Jan; 7(1):65-75. PubMed ID: 15652750
[TBL] [Abstract][Full Text] [Related]
20. Tumor microenvironment and neurofibromatosis type I: connecting the GAPs.
Le LQ; Parada LF
Oncogene; 2007 Jul; 26(32):4609-16. PubMed ID: 17297459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
